Italia markets closed
FTSE MIB
33.154,05 -32,84 (-0,10%) Dow Jones
39.118,86 -45,20 (-0,12%) Nasdaq
17.732,60 -126,08 (-0,71%) Nikkei 225
39.583,08 +241,54 (+0,61%) Petrolio
81,46 -0,28 (-0,34%) Bitcoin EUR
56.798,04 -556,81 (-0,97%)
ABBV Jan 2025 230.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 11:05AM EDT
| Chiusura precedente | 49,43 |
| Aperto | N/D |
| Denaro | 66,70 |
| Domanda | 68,80 |
| Prezzo d'esercizio | 230,00 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 49,43 - 49,43 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 2 |
GlobeNewswireAlector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00
© 2024 Yahoo. Tutti i diritti riservati.